R&D Center
We have established a global and fully integrated innovation-driven R&D system
National Major New Drug Development Projects
Pipeline Compounds Under Active Development
New Manufacturing Approvals
（Since 2018）
Provincial and Higher-Level Science & Technology
Domestic Granted Invention Patents
International Granted Invention Patents
R&D Strategy
Qingfeng Pharmaceutical Group adopts an R&D-driven development strategy, investing no less than 10% of its annual sales revenue into R&D each year. The company has established synergistic and efficient platforms in locations such as Shanghai, Beijing, Hangzhou, and Ganzhou, covering chemical innovative drugs, high-value generics, cell immunology, innovative natural medicine research, pilot-scale transformation, and biopharmaceutical innovation accelerators. Additionally, the company has built high-end R&D platforms such as national key laboratories, national enterprise technology centers, and national postdoctoral research stations, forming a global full-chain innovation R&D system and creating an open and cooperative innovation ecosystem within the pharmaceutical industry.
National Key Laboratory
National Enterprise Technology Center
National Postdoctoral Research Station
Provincial Key Laboratories
Provincial Engineering Research Centers
Provincial Engineering Technology Research Centers
Shanghai Pharmaceutical R&D Center
Hangzhou Pharmaceutical R&D Center
Ganzhou Pharmaceutical R&D Center
Beijing Clinical Registration Center
Shanghai
Hangzhou
Ganzhou
Beijing
Shanghai Pharmaceutical R&D Center
Center Positioning:
Headquarters of Qingfeng's R&D system, innovative drug design and screening platform, biopharmaceutical innovation accelerator
Center Introduction:
Headquarters of Qingfeng's R&D System
Located in Shanghai Zhangjiang Hi-Tech Park, a core area of China's biopharmaceutical industry, covering 3,000 square meters with advanced innovative drug R&D instruments and equipment.
Innovative drug design and screening platform
We are committed to the target design and screening of small molecule innovative drugs for unmet clinical needs, including those in the fields of oncology, antiviral, and immune modulation.
Biopharmaceutical Innovation Accelerator
The world's largest Class A biopharmaceutical innovation accelerator, invested and established by Qingfeng Group.
Hangzhou Pharmaceutical R&D Center
Center Positioning:
Innovative Drug CMC Transformation Platform, High-End Generic Drug R&D Platform, Polymorph Research Platform
Center Introduction:
The Hangzhou R&D Center specializes in small-scale research and formulation development for innovative drugs and high-end generics. Covering an area of 10,000 square meters, the center is staffed by over 130 dedicated R&D professionals. Its laboratories and platforms are designed and built to meet the standards of EU GMP, US FDA cGMP, and China GMP. The center adheres to an open philosophy and can undertake third-party pharmaceutical R&D services.
Ganzhou Pharmaceutical R&D Center
Center Positioning:
National Key Laboratory, Special Dosage Form Research Platform, Pilot Scale and Technology Transfer Platform
Center Introduction:
National Key Laboratory
The laboratory is one of the first national key laboratories in Jiangxi Province.Following its restructuring in 2023, the lab now participates in the joint development of the National Key Laboratory for Innovative Drug Innovation.
Special Dosage Form Research Platform
We have successfully developed high-end technology research platforms, including controlled-release, hot-melt extrusion, and osmotic pumps, establishing Qingfeng Pharmaceutical's core technological advantages.
Pilot Scale and Technology Transfer
The center is equipped with standardized laboratories and advanced domestic and international instruments, enabling us to independently conduct small-scale and pilot-scale research, as well as technology transfer for innovative drugs.
Beijing Clinical Registration Center
Center Positioning:
Registration Affairs, Clinical Center, Intellectual Property
Center Introduction:
As the company’s clinical research hub, the center oversees end-to-end clinical trial operations, regulatory registration submissions, and intellectual property management. including registration submissions, clinical site selection, SOP development, project management quality control, and rapid patient enrollment. It has built a clinical research network covering multidisciplinary areas such as oncology, cardiovascular, and neurological diseases. (Qingfeng also has clinical research platforms in Shanghai, Nanjing, and other locations.)
R&D Talent
At the heart of R&D-driven growth lies talent. To attract and retain top-tier professionals, Qingfeng Pharmaceutical has adopted a talent-centric strategy centered in Shanghai. By investing in innovative enterprises and implementing a clustered R&D development model, the company establishes corporate entities around highly innovative platforms and projects. Through mechanisms such as equity incentives, we have successfully attracted a diverse group of returnees and high-caliber professionals from multinational pharmaceutical companies.
R&D and technical professionals
employees holding master's or doctoral degrees
national-level high-level talents
Research Projects
The company has undertaken 9 national-level projects, including 7 major national science and technology projects for the development of innovative drugs, 1 national technological transformation project, and 1 national traditional Chinese medicine standardization project. All national-level projects have been successfully completed and accepted.
Number
Project Level
Specific categories
Project Name
Project Start and End Time
